Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Juan Pablo Frias. (2019) Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. Expert Review of Endocrinology & Metabolism 14:2, pages 75-83.
Read now
Read now
Francesco Giorgino, Alfred Penfornis, Valeria Pechtner, Raffaella Gentilella & Antonella Corcos. (2018) Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement. Patient Preference and Adherence 12, pages 707-719.
Read now
Read now
André J. Scheen. (2017) Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Review of Clinical Pharmacology 10:12, pages 1303-1316.
Read now
Read now
André J. Scheen. (2017) Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:5, pages 583-592.
Read now
Read now
Stuart A. Ross, A. Enrique Caballero, Stefano Del Prato, Baptist Gallwitz, Diane Lewis-D’Agostino, Zelie Bailes, Sandra Thiemann, Sanjay Patel, Hans-Juergen Woerle & Maximilian von Eynatten. (2016) Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. Postgraduate Medicine 128:8, pages 747-754.
Read now
Read now
Frank Lavernia, Sarah E. Adkins & Jay H. Shubrook. (2015) Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals. Postgraduate Medicine 127:8, pages 808-817.
Read now
Read now
André J Scheen. (2015) Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 1005-1020.
Read now
Read now
Ronnie Aronson. (2015) Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Current Medical Research and Opinion 31:5, pages 901-911.
Read now
Read now
Morgan Bron, Rajeev Ayyagari, Hari Sharma, Kristina Chen, Ana Bozas & Eric Wu. (2014) Management of Patients Using Combination Therapy With Pioglitazone and a Dipeptidyl Peptidase-4 Inhibitor: An Analysis of Initial Versus Sequential Combination Therapy. Postgraduate Medicine 126:3, pages 47-55.
Read now
Read now
Gina Cosentino, Ariane O Conrad & Gabriel I Uwaifo. (2013) Phentermine and topiramate for the management of obesity: a review. Drug Design, Development and Therapy 7, pages 267-278.
Read now
Read now
Articles from other publishers (34)
E. V. Biryukova & D. V. Kileynikov. (2023) Metformin and sitagliptin fixed combination as the optimal choice in solving current problems in the type 2 diabetes mellitus treatment. Meditsinskiy sovet = Medical Council 17:9, pages 23-30.
Crossref
Crossref
Qiran Wei, Jiting Zhou, Hongchao Li, Luying Wang, Yao Wu, Aixia Ma & Xin Guan. (2023) Medication adherence with fixed-dose versus free-equivalent combination therapies: Systematic review and meta-analysis. Frontiers in Pharmacology 14.
Crossref
Crossref
Yvonne Schnaars, Sumedh Gaikwad, Ulrike Gottwald-Hostalek, Wolfgang Uhl, Olga Ribot, Kanthikiran V. S. Varanasi, Laura Rodríguez, Javier Torrejón & Luis Gómez. (2022) Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products. Diabetes Therapy 14:2, pages 347-362.
Crossref
Crossref
Sang‐Jun Cho, In‐Sun Oh, Han Eol Jeong, Young Min Cho, Yul Hwangbo, Oriana Hoi Yun Yu & Ju‐Young Shin. (2022)
Long‐term
clinical outcomes of oral antidiabetic drugs as
fixed‐dose
combinations: A nationwide retrospective cohort study
. Diabetes, Obesity and Metabolism 24:10, pages 2051-2060.
Crossref
Crossref
Yvonne Schnaars, Sumedh Gaikwad, Ulrike Gottwald-Hostalek, Ulrike Klingberg, Hari Kiran Chary Vadla & Vamshi Ramana Prathap. (2022) Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers. Diabetes Therapy 13:6, pages 1215-1229.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Hirotaka Watada, Kazuyo Sasaki, Kazumi Mori-Anai, Tomohisa Iwasaki & Tatsuki Teranishi. (2022) Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan. Advances in Therapy 39:4, pages 1642-1658.
Crossref
Crossref
Ha Eun Choi, Ji Won Lee, Nam Kyung Je & Kyeong Hye Jeong. (2022) Use of SGLT2 inhibitor/metformin fixed dose combination in Korea. Korean Journal of Clinical Pharmacy 32:1, pages 13-19.
Crossref
Crossref
António Lopes, Fátima Roque, Sandra Morgado, Cristina Dinis, Maria Teresa Herdeiro & Manuel Morgado. (2021) Behavioral Sciences in the Optimization of Pharmacological and Non-Pharmacological Therapy for Type 2 Diabetes. Behavioral Sciences 11:11, pages 153.
Crossref
Crossref
Sara Denicolò, Paul Perco, Stefanie Thöni & Gert Mayer. (2021) Non-adherence to antidiabetic and cardiovascular drugs in type 2 diabetes mellitus and its association with renal and cardiovascular outcomes: A narrative review. Journal of Diabetes and its Complications 35:7, pages 107931.
Crossref
Crossref
Philip Home, Lawrence Blonde, Sanjay Kalra, Linong Ji, Patricia Guyot, Claire Brulle‐Wohlhueter, Erin Murray, Roshan Shah, Toby Sayre & Alka Shaunik. (2020)
Insulin glargine/lixisenatide fixed‐ratio combination (
iGlarLixi
) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis
. Diabetes, Obesity and Metabolism 22:11, pages 2179-2188.
Crossref
Crossref
Ana Baumgartner, Katarina Drame, Stijn Geutjens & Marja Airaksinen. (2020) Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review. Pharmaceutics 12:2, pages 190.
Crossref
Crossref
Otto Mayer. (2019) How serious problem is poor adherence to treatment in coronary artery disease?. Intervenční a akutní kardiologie 18:3, pages 138-142.
Crossref
Crossref
Robert Schlosser. (2019) Fixed-Dose and Fixed-Ratio Combination Therapies in Type 2 Diabetes. Canadian Journal of Diabetes 43:6, pages 440-444.
Crossref
Crossref
Fernando Perez-Ruiz & Nicola Dalbeth. (2019) Combination urate-lowering therapy in the treatment of gout: What is the evidence?. Seminars in Arthritis and Rheumatism 48:4, pages 658-668.
Crossref
Crossref
N. A. PetuninaA. L. Terekhova. (2019) Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Medical Council:21, pages 138-145.
Crossref
Crossref
Mitsuyoshi Takahara, Toshihiko Shiraiwa, Naoto Katakami, Yoshifumi Maeno, Kaoru Yamamoto, Yuka Shiraiwa, Yoko Yoshida, Taka-aki Matsuoka & Iichiro Shimomura. (2019) Different daily glycemic profiles after switching from once-daily alogliptin plus twice-daily metformin to their once-daily fixed-dose combination in Japanese type 2 diabetic patients. Endocrine Journal 66:1, pages 11-17.
Crossref
Crossref
György Jermendy, Zoltán Kiss, György Rokszin, Zsolt Abonyi-Tóth, István Wittmann & Péter Kempler. (2018) Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study. Diabetes Therapy 9:5, pages 2133-2141.
Crossref
Crossref
Luc Trudeau & Jeremy Gilbert. (2018) Diabetes and Hypertension: The Low and High Points. Canadian Journal of Diabetes 42:2, pages 113-114.
Crossref
Crossref
Eugenio Cersosimo, Eric L. Johnson, Christina Chovanes & Neil Skolnik. (2018) Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes, Obesity and Metabolism 20:3, pages 497-507.
Crossref
Crossref
Sanjay Kalra, Silver Bahendeka, Rakesh Sahay, Sujoy Ghosh, Fariduddin Md, Abbas Orabi, Kaushik Ramaiya, Sameer Al Shammari, Dina Shrestha, Khalid Shaikh, Sachitha Abhayaratna, PradeepK Shrestha, Aravinthan Mahalingam, Mazen Askheta, AlyAhmed A. Rahim, Fatimah Eliana, HariK Shrestha, Sandeep Chaudhary, Nancy Ngugi, JeanClaude Mbanya, ThanThan Aye, TintSwe Latt, ZhanayA Akanov, AbbasRaza Syed, Nikhil Tandon, AG Unnikrishnan, SV Madhu, Ali Jawa, Subhankar Chowdhury, Sarita Bajaj & AshokKumar Das. (2018) Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force. Indian Journal of Endocrinology and Metabolism 22:1, pages 132.
Crossref
Crossref
Harpreet S. Bajaj, Chenglin Ye, Esha Jain, Karri Venn, Eden Stein & Ronnie Aronson. (2017)
Glycemic Improvement with a Fixed‐dose combination of
DPP
‐4 inhibitor + metformin in patients with Type 2 diabetes (
GIFT
study)
. Diabetes, Obesity and Metabolism 20:1, pages 195-199.
Crossref
Crossref
Cristina Bianchi, Giuseppe Daniele, Angela Dardano, Roberto Miccoli & Stefano Del Prato. (2017) Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs 77:3, pages 247-264.
Crossref
Crossref
S. C. Bain, M. Feher, D. Russell-Jones & K. Khunti. (2016) Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. Diabetes, Obesity and Metabolism 18:12, pages 1157-1166.
Crossref
Crossref
Kaori Koyanagi, Toshio Kubota, Daisuke Kobayashi, Taro Kihara, Takeo Yoshida, Takamasa Miisho, Tomoko Miura, Yoshiko Sakamoto, Junichi Takaki, Takashi Seo & Takao Shimazoe. (2016) Prescription Factors Associated with Medication Non-adherence in Japan Assessed from Leftover Drugs in the SETSUYAKU-BAG Campaign: Focus on Oral Antidiabetic Drugs. Frontiers in Pharmacology 7.
Crossref
Crossref
Vicki S. Conn, Todd M. Ruppar, RN, Maithe Enriquez & Pamela S. Cooper. (2016) Patient-Centered Outcomes of Medication Adherence Interventions: Systematic Review and Meta-Analysis. Value in Health 19:2, pages 277-285.
Crossref
Crossref
Sreeraj Macha, Tobias Brand, Thomas Meinicke, Jasmin Link & Uli C. Broedl. (2015) Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects. Clinical Therapeutics 37:8, pages 1789-1796.
Crossref
Crossref
S. A. Ross, A. E. Caballero, S. Del Prato, B. Gallwitz, D. Lewis‐D'Agostino, Z. Bailes, S. Thiemann, S. Patel, H.‐J. Woerle & M. von Eynatten. (2014) Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double‐blind, active‐controlled, parallel group, multinational clinical trial. Diabetes, Obesity and Metabolism 17:2, pages 136-144.
Crossref
Crossref
Thomas Haak. (2015) Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes. Clinical Medicine Insights: Endocrinology and Diabetes 8, pages CMED.S10360.
Crossref
Crossref
Grigorios Rombopoulos, Magdalini Hatzikou, Athanasios Athanasiadis & Moyses Elisaf. (2015) Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study. International Journal of Endocrinology 2015, pages 1-5.
Crossref
Crossref
Megan Dingwall & Justin Moore. (2014) Combination pill effective, but expensive. Obesity 22:8, pages 1772-1772.
Crossref
Crossref
Jaime A Davidson, Rosemarie Lajara, Richard B Aguilar, Michaela Mattheus, Hans-Juergen Woerle & Maximilian von Eynatten. (2014) Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials. BMJ Open Diabetes Research & Care 2:1, pages e000020.
Crossref
Crossref
Benjamin S. SzwergoldCraig B. Miller. (2014)
Potential of Birds to Serve as a Pathology-Free Model of Type 2 Diabetes, Part 1: Is the Apparent Absence of the
RAGE
Gene a Factor in the Resistance of Avian Organisms to Chronic Hyperglycemia?
. Rejuvenation Research 17:1, pages 54-61.
Crossref
Crossref
Luis-Emilio García-Pérez, María Álvarez, Tatiana Dilla, Vicente Gil-Guillén & Domingo Orozco-Beltrán. (2013) Adherence to Therapies in Patients with Type 2 Diabetes. Diabetes Therapy 4:2, pages 175-194.
Crossref
Crossref
Jun-Sing Wang, Chien-Ning Huang, Yi-Jen Hung, Ching-Fai Kwok, Jui-Hung Sun, Dee Pei, Chwen-Yi Yang, Ching-Chu Chen, Ching-Ling Lin & Wayne Huey-Herng Sheu. (2013) Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Research and Clinical Practice 102:1, pages 16-24.
Crossref
Crossref